Literature DB >> 19651363

Principles and analytical performance of Abbott RealTime High Risk HPV test.

Shihai Huang1, Ning Tang, Wai-Bing Mak, Brian Erickson, John Salituro, Yuhong Li, Evelyn Krumpe, George Schneider, Hong Yu, John Robinson, Klara Abravaya.   

Abstract

BACKGROUND: Abbott RealTime High Risk (HR) HPV is a new automated, qualitative real-time PCR test for detection of DNA from 14 high-risk human papillomavirus (HPV) types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) in cervical specimens. The test can also differentiate between HPV 16, HPV 18 and non-HPV 16/18 types in a single reaction.
OBJECTIVES: This article describes the principles of assay design and the analytical performance of Abbott RealTime HR HPV. STUDY
DESIGN: The analytical performance characteristics of Abbott RealTime HR HPV were evaluated in terms of its sensitivity for each of the 14 high-risk types included in the test, specificity (cross-reactivity), potential for interference by substances that may be present in cervical specimens, and reproducibility.
RESULTS: Abbott RealTime HR HPV provided sensitive detection of the 14 high-risk HPV types included in the test. It was also highly specific to the HPV types targeted by the test and did not show cross-reactivity with 15 low-risk HPV types tested, or non-specific reactivity with other common microorganisms that may be present in the female anogenital tract. Test results were not impacted by potential interfering substances evaluated in the study. The test generated highly reproducible results in an in-house study and in studies carried out at 13 external evaluation sites.
CONCLUSIONS: Abbott RealTime HR HPV demonstrated a robust analytical performance with reproducible and reliable results.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19651363     DOI: 10.1016/S1386-6532(09)70003-4

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  13 in total

1.  Oral and oropharyngeal papillomas are not associated with high-risk human papillomavirus infection.

Authors:  Miroslaw Snietura; Roman Lamch; Agnieszka Kopec; Dariusz Waniczek; Wirginia Likus; Dariusz Lange; Jaroslaw Markowski
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-06-21       Impact factor: 2.503

2.  Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening.

Authors:  A T Hesselink; C J L M Meijer; M Poljak; J Berkhof; F J van Kemenade; M L van der Salm; M Bogaarts; P J F Snijders; D A M Heideman
Journal:  J Clin Microbiol       Date:  2013-05-01       Impact factor: 5.948

3.  Development of sensitive single-round pol or env RT-PCR assays to screen for XMRV in multiple sample types.

Authors:  Ning Tang; Andrea Frank; Gregor Leckie; John Hackett; Graham Simmons; Michael Busch; Klara Abravaya
Journal:  J Virol Methods       Date:  2011-10-25       Impact factor: 2.014

Review 4.  Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy.

Authors:  Patti E Gravitt; Jerome L Belinson; Jorge Salmeron; Keerti V Shah
Journal:  Int J Cancer       Date:  2011-08-01       Impact factor: 7.396

5.  Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.

Authors:  Mario Poljak; Anja Ostrbenk; Katja Seme; Veronika Ucakar; Peter Hillemanns; Eda Vrtacnik Bokal; Nina Jancar; Irena Klavs
Journal:  J Clin Microbiol       Date:  2011-03-23       Impact factor: 5.948

6.  A Randomized Clinical Trial of Human Papillomavirus Test-and-Treat as Compared to Cytology-Based Screening for Prevention of Cervical Cancer Among Women With Human Immunodeficiency Virus: AIDS Clinical Trials Group Protocol A5282.

Authors:  Timothy Wilkin; Huichao Chen; Vikrant Sahasrabuddhe; Roy Matining; Rosie Mngqibisa; Lameck Chinula; Yamikani Mbilizi; Tsitsi Magure; Ayotunde E Omoz-Oarhe; Mohammed Rassool; Cynthia Riviere; Rhamesh Bhosale; Sheela Godbole; Reena Naranjo; Robert Coombs; Pamela Michelow; Catherine Godfrey; Cynthia Firnhaber
Journal:  Clin Infect Dis       Date:  2022-10-12       Impact factor: 20.999

7.  Potential role of human papilloma virus in the pathogenesis of gastric cancer.

Authors:  Miroslaw Snietura; Dariusz Waniczek; Wojciech Piglowski; Agnieszka Kopec; Ewa Nowakowska-Zajdel; Zbigniew Lorenc; Malgorzata Muc-Wierzgon
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

8.  Performance of a New HPV Cervi-Collect Collection and Transportation Kit.

Authors:  M Chernesky; S Huang; D Jang; B Erickson; J Salituro; H Engel; J Gilchrist; P Neuscheler; W B Mak; K Abravaya
Journal:  J Oncol       Date:  2011-11-14       Impact factor: 4.375

9.  Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott RealTime High Risk human papillomavirus test, and the Hybrid Capture human papillomavirus DNA test for the detection of human papillomavirus.

Authors:  Yusun Hwang; Miae Lee
Journal:  Ann Lab Med       Date:  2012-04-18       Impact factor: 3.464

10.  Establishment of immunoassay for detecting HPV16 E6 and E7 RNA.

Authors:  Sen Ding; Steven Y Qian; Yang Zhang; Wenlei Wu; Gensheng Lu; Yan Lu; Xiujing Feng; Li Li; Pingping Shen
Journal:  Sci Rep       Date:  2015-09-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.